Iovino Claudio, Chhablani Jay, Rasheed Mohammed Abdul, Tatti Filippo, Bernabei Federico, Pellegrini Marco, Giannaccare Giuseppe, Peiretti Enrico
Department of Surgical Sciences, Eye Clinic, University of Cagliari, Cagliari, Italy.
Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA.
Eye (Lond). 2021 Mar;35(3):913-918. doi: 10.1038/s41433-020-0995-9. Epub 2020 May 28.
To evaluate choroidal vasculature changes after the instillation of mydriatic parasympatholytic and sympathomimetic agents in healthy subjects.
A total of 95 healthy subjects were enrolled in this prospective, randomized comparative study. Study participants were divided into three different groups depending on the drug to be administered: tropicamide (1%) group (n = 31), tropicamide (0.5%) + phenylephrine (10%) group (n = 30) and control group receiving artificial tears (n = 34). All participants underwent a complete ophthalmological examination including best corrected visual acuity, refractive status and axial length. Subfoveal choroidal thickness (CT), total choroidal area (TCA), luminal and stromal choroidal area (LCA and SCA) and choroidal vascularity index (CVI) were measured before and after eye drops instillation.
All the baseline characteristics were matched between the three groups (all P > 0.05). Before the mydriatic instillation, there were no significant differences of CT, TCA, LA, SCA, and CVI among the three groups (all P > 0.05). After drug administration, CT, TCA, LCA, SCA, and CVI did not show any significant change as well (respectively, P = 0.265; P = 0.483; 0.573; P = 0.405 and P = 0.708).
Instillation of mydriatic eye drops did not induce significant changes of the choroidal vasculature, suggesting that their use do not alter CT and CVI evaluation.
评估在健康受试者中滴入散瞳的副交感神经阻滞剂和拟交感神经药后脉络膜血管系统的变化。
95名健康受试者参与了这项前瞻性随机对照研究。根据所给予的药物,研究参与者被分为三组:托吡卡胺(1%)组(n = 31)、托吡卡胺(0.5%)+ 去氧肾上腺素(10%)组(n = 30)和接受人工泪液的对照组(n = 34)。所有参与者均接受了包括最佳矫正视力、屈光状态和眼轴长度在内的全面眼科检查。在滴眼药水前后测量黄斑中心凹下脉络膜厚度(CT)、脉络膜总面积(TCA)、脉络膜管腔和基质面积(LCA和SCA)以及脉络膜血管指数(CVI)。
三组之间所有基线特征均匹配(所有P > 0.05)。在散瞳滴眼之前,三组之间的CT、TCA、LA、SCA和CVI均无显著差异(所有P > 0.05)。给药后,CT、TCA、LCA、SCA和CVI也未显示出任何显著变化(分别为P = 0.265;P = 0.483;0.573;P = 0.405和P = 0.708)。
滴入散瞳眼药水未引起脉络膜血管系统的显著变化,表明其使用不会改变CT和CVI评估。